无套内射无矿码免费看黄_亚洲精品嫩草AV在线观看_久久久久久国产精品免费免费男同_正在播放少妇呻吟对白_亚洲日韩欧美成人久久_色哟哟国产精品免费观看_4d肉蒲团之性奴大战奶水_人人妻人人澡人人爽_国产精品熟女在线视频_野外做受三级视频

Seragon Pharmaceuticals  
Seragon Pharmaceuticals 前身是Aragon的乳癌藥物開發(fā)部門

Seragon Pharmaceuticals’ orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon’s most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon’s SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.